 |
|
|
| |
Evaluation of Fasting Lipids and Insulin Resistance After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily: Week 48 Results From Two Randomized Phase 3 Studies in Adults Living With HIV-1
|
| |
| |
Presented at the 20th European AIDS Conference (EACS); Paris, France; October 15-18, 2025
|
| |
|
|
|
|
|
